Literature DB >> 16645318

Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.

Jaroslav Racek1, Hana Králová, Ladislav Trefil, Daniel Rajdl, Jaromír Eiselt.   

Abstract

BACKGROUND: Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are released into circulation as a result of congestive heart failure (HF). As HF and water overload are frequent complications in haemodialysis (HD) patients, we decided to study the levels of BNP and NT-proBNP and their changes during HD.
METHODS: BNP and NT-proBNP levels were determined in 94 HD patients before and after a regular 4-h HD. We followed changes in these peptides during HD depending on age, sex, HF (NYHA classification and left ventricular ejection fraction [LVEF]), duration on HD, presence of hypertension, coronary artery disease, type of membrane used for HD [low-flux (LFx) or high-flux (HFx)] and body mass change during HD. Furthermore, patients basic medication and creatinine levels and presence of diabetes mellitus were monitored.
RESULTS: Respectively,94% and 100% of the patients had pre-dialysis concentrations of BNP and NT-proBNP above the cut-off values for HF. The marker levels correlated significantly both before and after HD (r = 0.903 and 0.888, respectively, p < 0.001). BNP levels significantly decreased (p < 0.0001), whereas NT-proBNP significantly increased (p < 0.0001) during HD on LFx membranes. HD on HFx membranes caused greater decrease of BNP (compared to LFx membranes, p < 0.001), but also a decrease of NT-proBNP (p < 0.001).We did not find any significant differences in marker levels for HF and non-HF patients (NYHA classification). However, both peptides reached higher levels in the group with LVEF < or = 50% (p < 0.001 for both peptides). Body mass change during HD negatively correlated only with the change of NT-proBNP (r = -0.27, p < 0.05). In the multiple regression model, the change of both peptides during HD was significantly influenced by membrane type (p = 0.003 for BNP and p = 0.001 for NT-proBNP). NT-proBNP change during HD was further significantly influenced by LVEF (p = 0.012), sex (p = 0.002) and duration on HD (p = 0.006).
CONCLUSIONS: Both BNP and NT-proBNP levels were significantly increased in HD patients prior to dialysis. The change in concentrations of both peptides during HD is influenced by membrane type. HD probably triggers increased production of both peptides and this increase is emphasized by impaired LVEF. This fact can be clinically observed only on NT-proBNP levels, because BNP levels are biased by significant removal of this protein during HD. Copyright 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645318     DOI: 10.1159/000092914

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  16 in total

1.  Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Authors:  Patrícia João Matias; Cristina Jorge; Carina Ferreira; Marília Borges; Inês Aires; Tiago Amaral; Célia Gil; José Cortez; Aníbal Ferreira
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

2.  Plasma Brain Natriuretic Peptide Levels in Cardiac Function Assessment in Chronic Dialysis Patients.

Authors:  R Sanjuan; S Martín Oliva; M L Blasco; M Puchades; I Torregrosa; R García Ramón; A Miguel Carrasco
Journal:  Cardiorenal Med       Date:  2011-07-01       Impact factor: 2.041

Review 3.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

4.  Biomarkers in predicting mortality and treatment in hemodialysis patients.

Authors:  Angela Yee-Moon Wang
Journal:  F1000 Med Rep       Date:  2009-03-17

5.  Serum levels of N-terminal pro-B-type natriuretic peptide are associated with allograft function in recipients of renal transplants.

Authors:  Gerd Bodlaj; Rainer Hubmann; Karim Saleh; Georg Biesenbach; Erich Pohanka; Tatjana Stojakovic; Jörg Berg
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

6.  Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial.

Authors:  Ramon Paniagua; Dante Amato; Salim Mujais; Edward Vonesh; Alfonso Ramos; Ricardo Correa-Rotter; Walter H Horl
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 8.237

Review 7.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

8.  Simultaneous predictive value of NT-proBNP and CA-125 in patients newly diagnosed with advanced heart failure: preliminary results.

Authors:  Andrzej Folga; Krzysztof J Filipiak; Artur Mamcarz; Elzbieta Obrebska-Tabaczka; Grzegorz Opolski
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

9.  Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Authors:  Joanna Leigh Dunlop; Alain Charles Vandal; Janak Rashme de Zoysa; Ruvin Sampath Gabriel; Imad Adbi Haloob; Christopher John Hood; Philip James Matheson; David Owen Ross McGregor; Kannaiyan Samuel Rabindranath; David John Semple; Mark Roger Marshall
Journal:  BMC Nephrol       Date:  2013-07-15       Impact factor: 2.388

10.  The NT-ProBNP Test in Subjects with End-Stage Renal Disease on Hemodialysis Presenting with Acute Dyspnea: Is Knowing Worth the Cost?

Authors:  Shaffer R S Mok; Jose Avila; Barry Milcarek; Richard Kasama
Journal:  Emerg Med Int       Date:  2013-03-07       Impact factor: 1.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.